Article
Merck has confirmed that the FDA Nonprescription Drug Advisory Committee proposed that the FDA consider labeling modifications as part of its review of oxybutynin transdermal system (Oxytrol) as an over-the-counter treatment for overactive bladder in women.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.